Linked Life Data

15994288

Source:http://linkedlifedata.com/resource/pubmed/id/15994288

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15994288rdf:typepubmed:Citationlld:pubmed
pubmed-article:15994288lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:15994288lifeskim:mentionsumls-concept:C0001792lld:lifeskim
pubmed-article:15994288lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:15994288lifeskim:mentionsumls-concept:C0080103lld:lifeskim
pubmed-article:15994288lifeskim:mentionsumls-concept:C0376622lld:lifeskim
pubmed-article:15994288lifeskim:mentionsumls-concept:C1704939lld:lifeskim
pubmed-article:15994288lifeskim:mentionsumls-concept:C0023467lld:lifeskim
pubmed-article:15994288lifeskim:mentionsumls-concept:C0010711lld:lifeskim
pubmed-article:15994288lifeskim:mentionsumls-concept:C0011015lld:lifeskim
pubmed-article:15994288lifeskim:mentionsumls-concept:C0011900lld:lifeskim
pubmed-article:15994288lifeskim:mentionsumls-concept:C0449438lld:lifeskim
pubmed-article:15994288lifeskim:mentionsumls-concept:C0332287lld:lifeskim
pubmed-article:15994288lifeskim:mentionsumls-concept:C1823242lld:lifeskim
pubmed-article:15994288lifeskim:mentionsumls-concept:C0450442lld:lifeskim
pubmed-article:15994288lifeskim:mentionsumls-concept:C0139121lld:lifeskim
pubmed-article:15994288lifeskim:mentionsumls-concept:C1522609lld:lifeskim
pubmed-article:15994288lifeskim:mentionsumls-concept:C1554112lld:lifeskim
pubmed-article:15994288pubmed:issue8lld:pubmed
pubmed-article:15994288pubmed:dateCreated2005-10-5lld:pubmed
pubmed-article:15994288pubmed:abstractTextTo determine whether MDR1 reversal by the addition of the P-glycoprotein (P-gp) inhibitor PSC-833 to standard induction chemotherapy would improve event-free survival (EFS), 419 untreated patients with acute myeloid leukemia (AML) aged 60 years and older were randomized to receive 2 induction cycles of daunorubicin and cytarabine with or without PSC-833. Patients in complete remission were then given 1 consolidation cycle without PSC-833. Neither complete response (CR) rate (54% versus 48%; P = .22), 5-year EFS (7% versus 8%; P = .53), disease-free survival (DFS; 13% versus 17%; P = .06) nor overall survival (OS; 10% in both arms; P = .52) were significantly improved in the PSC-833 arm. An integrated P-gp score (IPS) was determined based on P-gp function and P-gp expression in AML cells obtained prior to treatment. A higher IPS was associated with a significantly lower CR rate and worse EFS and OS. There was no significant interaction between IPS and treatment arm with respect to CR rate and survival, indicating also a lack of benefit of PSC-833 in P-gp-positive patients. The role of strategies aimed at inhibitory P-gp and other drug-resistance mechanisms continues to be defined in the treatment of patients with AML.lld:pubmed
pubmed-article:15994288pubmed:languageenglld:pubmed
pubmed-article:15994288pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15994288pubmed:citationSubsetAIMlld:pubmed
pubmed-article:15994288pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15994288pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15994288pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15994288pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15994288pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15994288pubmed:statusMEDLINElld:pubmed
pubmed-article:15994288pubmed:monthOctlld:pubmed
pubmed-article:15994288pubmed:issn0006-4971lld:pubmed
pubmed-article:15994288pubmed:authorpubmed-author:PiccalugaPier...lld:pubmed
pubmed-article:15994288pubmed:authorpubmed-author:LöwenbergBobBlld:pubmed
pubmed-article:15994288pubmed:authorpubmed-author:CrumpMichaelMlld:pubmed
pubmed-article:15994288pubmed:authorpubmed-author:SonneveldPiet...lld:pubmed
pubmed-article:15994288pubmed:authorpubmed-author:VellengaEdoElld:pubmed
pubmed-article:15994288pubmed:authorpubmed-author:OssenkoppeleG...lld:pubmed
pubmed-article:15994288pubmed:authorpubmed-author:ShepherdJohnJlld:pubmed
pubmed-article:15994288pubmed:authorpubmed-author:TheobaldMatth...lld:pubmed
pubmed-article:15994288pubmed:authorpubmed-author:BurnettAlan...lld:pubmed
pubmed-article:15994288pubmed:authorpubmed-author:van der...lld:pubmed
pubmed-article:15994288pubmed:authorpubmed-author:FeyMartin FMFlld:pubmed
pubmed-article:15994288pubmed:authorpubmed-author:SelleslagDomi...lld:pubmed
pubmed-article:15994288pubmed:authorpubmed-author:FerrantAugust...lld:pubmed
pubmed-article:15994288pubmed:authorpubmed-author:VerhoefGregor...lld:pubmed
pubmed-article:15994288pubmed:authorpubmed-author:DuganMargaret...lld:pubmed
pubmed-article:15994288pubmed:authorpubmed-author:KnaufWolfgang...lld:pubmed
pubmed-article:15994288pubmed:issnTypePrintlld:pubmed
pubmed-article:15994288pubmed:day15lld:pubmed
pubmed-article:15994288pubmed:volume106lld:pubmed
pubmed-article:15994288pubmed:ownerNLMlld:pubmed
pubmed-article:15994288pubmed:authorsCompleteYlld:pubmed
pubmed-article:15994288pubmed:pagination2646-54lld:pubmed
pubmed-article:15994288pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:15994288pubmed:meshHeadingpubmed-meshheading:15994288...lld:pubmed
pubmed-article:15994288pubmed:meshHeadingpubmed-meshheading:15994288...lld:pubmed
pubmed-article:15994288pubmed:meshHeadingpubmed-meshheading:15994288...lld:pubmed
pubmed-article:15994288pubmed:meshHeadingpubmed-meshheading:15994288...lld:pubmed
pubmed-article:15994288pubmed:meshHeadingpubmed-meshheading:15994288...lld:pubmed
pubmed-article:15994288pubmed:meshHeadingpubmed-meshheading:15994288...lld:pubmed
pubmed-article:15994288pubmed:meshHeadingpubmed-meshheading:15994288...lld:pubmed
pubmed-article:15994288pubmed:meshHeadingpubmed-meshheading:15994288...lld:pubmed
pubmed-article:15994288pubmed:meshHeadingpubmed-meshheading:15994288...lld:pubmed
pubmed-article:15994288pubmed:meshHeadingpubmed-meshheading:15994288...lld:pubmed
pubmed-article:15994288pubmed:meshHeadingpubmed-meshheading:15994288...lld:pubmed
pubmed-article:15994288pubmed:meshHeadingpubmed-meshheading:15994288...lld:pubmed
pubmed-article:15994288pubmed:meshHeadingpubmed-meshheading:15994288...lld:pubmed
pubmed-article:15994288pubmed:meshHeadingpubmed-meshheading:15994288...lld:pubmed
pubmed-article:15994288pubmed:meshHeadingpubmed-meshheading:15994288...lld:pubmed
pubmed-article:15994288pubmed:year2005lld:pubmed
pubmed-article:15994288pubmed:articleTitleThe value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.lld:pubmed
pubmed-article:15994288pubmed:affiliationDepartment of Hematology, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands. p.sonneveld@erasmusmc.nl.lld:pubmed
pubmed-article:15994288pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15994288pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:15994288pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:15994288pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15994288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15994288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15994288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15994288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15994288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15994288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15994288lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15994288lld:pubmed